RecruitingNCT06953180
Epigenetics and NCD Prevention in Kazakhstan: Personalized Approaches and Biological Age Prediction
Epigenetics and Prevention of Non-communicable Diseases in Kazakhstan: a Personalized Approach and Biological Age Prediction
Sponsor
Asfendiyarov Kazakh National Medical University
Enrollment
6,720 participants
Start Date
Mar 3, 2025
Study Type
OBSERVATIONAL
Conditions
Summary
This study aims to enhance personalized and preventive care for non-communicable diseases (NCDs) in Kazakhstan by examining epigenetic factors, predicting biological age and reproductive function using machine learning, and developing health improvement recommendations.
Eligibility
Min Age: 18 YearsMax Age: 69 Years
Inclusion Criteria3
- Adults aged 18 to 69 years.
- Residents of 17 regions of Kazakhstan.
- Willingness to participate and provide informed consent.
Exclusion Criteria2
- Age less than 18 years old or over 69 years old.
- Failure to provide informed consent or incomplete participation in data collection procedures.
Interventions
OTHERGenetic: DNA analysis
Investigation of telomere length (TL) and DNA methylation level analysis
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06953180
Related Trials
Safety and Tolerability of Difelikefalin in Adolescents on Haemodialysis With Moderate-to-Severe Pruritus
NCT0659339212 locations
Trial Against INtractable Type 2 Diabetes (CAPTAIN-T2D)
NCT0729648446 locations
Molecular Prediction of Development, Progression or Complications of Kidney, Immune or Transplantation-related Diseases
NCT053181961 location
Using Continuous Glucose Monitoring to Quantify the Effects of NOURISH's Culturally Modified Meals on Asian Americans With Type 2 Diabetes
NCT068364791 location
Improving Kidney Care in Type 2 Diabetes: A Study of Pharmacist Prescribing Versus Usual Care
NCT071694221 location